Antegrade Medical Inc. successfully closed a CAD $7.3 million Series Seed financing round to advance the development of innovative minimally invasive cardiology instruments.
Target Company Overview
Antegrade Medical Inc. ("Antegrade") is an innovative medical device company based in Quebec City, Quebec, dedicated to developing advanced instruments for minimally invasive interventional cardiology procedures. The company aims to facilitate complex interventions by creating specialized tools tailored for high-risk patients suffering from structural heart diseases, valve diseases, and heart failure.
Founded under the leadership of Louis Laflamme, CPA, who has a notable track record in the cardiology field, Antegrade seeks to revolutionize patient care by enhancing outcomes through cutting-edge medical technologies. Among its co-founders is Dr. Gennaro Giustino, an experienced interventional cardiologist known for pioneering techniques in complex cardiac procedures.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview
In Canada, the medical device industry, particularly within the field of cardiology, is witnessing substantial growth, propelled by an increasing prevalence of heart dis
Similar Deals
Sectoral Asset Management, Genesys Capital, Desjardins Capital, Seido Capital, Private Investors
invested in
Antegrade Medical Inc.
in 2025
in a Seed Stage deal
Disclosed details
Transaction Size: $5M